Kastelein Johannes Jacob Pieter

CIK 00020003891 companyNAARDEN, P7

SEC Profile

Transactions

Companies

Filings

CIK

0002000389

Recent Transactions

19 trades

Award
NewAmsterdam Pharma Co N.V.$NAMS
Option (right to buy)
2026-01-07+115,000→ 115,000 total
Award
NewAmsterdam Pharma Co N.V.$NAMS
Ordinary Shares
2026-01-07+25,500→ 98,981 total
Sale
NewAmsterdam Pharma Co N.V.$NAMS
Ordinary Shares
2026-01-05$33.25/sh−6,000→ 73,481 total
Sale
NewAmsterdam Pharma Co N.V.$NAMS
Ordinary Shares
2025-08-22$25.49/sh−7,658→ 69,302 total
Sale
NewAmsterdam Pharma Co N.V.$NAMS
Ordinary Shares
2025-08-22$25.08/sh−42,342→ 76,960 total
Sale
NewAmsterdam Pharma Co N.V.$NAMS
Ordinary Shares
2025-08-21$24.29/sh−50,000→ 119,302 total
Award
NewAmsterdam Pharma Co N.V.$NAMS
Ordinary Shares
2025-03-26+19,302→ 169,302 total
Exercise/Conversion
NewAmsterdam Pharma Co N.V.$NAMS
Ordinary Shares
2025-03-26+45,481→ 79,481 total
Exercise/Conversion
NewAmsterdam Pharma Co N.V.$NAMS
Restricted Stock Unit
2025-03-26−45,481→ 0 total
Award
NewAmsterdam Pharma Co N.V.$NAMS
Restricted Stock Unit
2025-03-26+45,481→ 45,481 total
Exercise/Conversion
NewAmsterdam Pharma Co N.V.$NAMS
Option (right to buy)
2025-03-24−150,000→ 820,229 total
Exercise/Conversion
NewAmsterdam Pharma Co N.V.$NAMS
Ordinary Shares
2025-03-24+150,000→ 150,000 total
Award
NewAmsterdam Pharma Co N.V.$NAMS
Ordinary Shares
2025-01-07+34,000→ 34,000 total
Award
NewAmsterdam Pharma Co N.V.$NAMS
Option (right to buy)
2025-01-02+200,000→ 200,000 total
Tax Payment
NewAmsterdam Pharma Co N.V.$NAMS
Ordinary Shares
2024-03-26$22.72/sh−11,197→ 190,476 total
Exercise/Conversion
NewAmsterdam Pharma Co N.V.$NAMS
Ordinary Shares
2024-03-26+201,673→ 201,673 total
Sale
NewAmsterdam Pharma Co N.V.$NAMS
Ordinary Shares
2024-03-26$21.50/sh−190,476→ 0 total
Exercise/Conversion
NewAmsterdam Pharma Co N.V.$NAMS
Option (right to buy)
2024-03-26−201,673→ 970,229 total
Award
NewAmsterdam Pharma Co N.V.$NAMS
Option (right to buy)
2024-01-01+500,000→ 500,000 total

Companies

NewAmsterdam Pharma Co N.V.
Director, Chief Scientific Officer
$NAMS

Recent Filings

Address

C/O NEWAMSTERDAM PHARMA COMPANY N.V. GOOIMEER 2-35

NAARDEN, P7, 1411 DC

View on SEC.gov